Skip to main content
. Author manuscript; available in PMC: 2013 Oct 30.
Published in final edited form as: J Psychiatr Res. 2010 Sep 9;45(4):10.1016/j.jpsychires.2010.07.011. doi: 10.1016/j.jpsychires.2010.07.011

Fig. 5.

Fig. 5

a: Levels of total-tau in the CSF of NNC vs. NPH: Human total-tau ELISA was performed with equal volume of CSF samples which showed no significant change in the CSF of NPH vs. NNC subjects (p = 0.519). b: Levels of phospho-tau in the CSF of NNC vs. NPH: Human phospho-tau ELISA was performed as described in ‘Materials and Methods’ section, which showed no significant change in phospho-tau levels in the CSF of NPH patients vs. NNC subjects (p = 0.153). c: Levels of total-tau in the CSF of NNC vs. NPH patients suffering more than one year: No significant change was observed in the levels of total-tau in the CSF samples of NNC vs. NPH subjects who were suffering from more than one year (p = 0.11). d: Levels of phospho-tau in the CSF of NNC vs. NPH patients suffering more than one year: A significant increase in phospho-tau is observed in the CSF of the patients who are suffering from the disease for more than one year (p = 0.013)(Out of twenty three NPH patients, duration of illness of seven patients was less than one year, nine patients were suffering from more than one year and data from seven patients were not obtained).